Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma (TACTIC-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03880279
Recruitment Status : Withdrawn (Following a change in company governance, Triumvira terminated the study prior to enrolling any subjects due to a challenging competitive landscape.)
First Posted : March 19, 2019
Last Update Posted : February 23, 2022
Information provided by (Responsible Party):
Triumvira Immunologics, Inc.

Brief Summary:
Phase I/II study to evaluate TAC01-CD19 in subjects with relapsed or refractory B-cell lymphomas. TAC technology is a novel way to genetically modify T cells and to redirect these T cells to target cancer antigens by co-opting the natural T cell receptor. The dose finding portion of this study will evaluate the safety and tolerability of increasing dose levels of TAC01-CD19 to identify a Maximal Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D). The dose expansion portion of the study will further evaluate the safety, efficacy and pharmacokinetics of TAC01-CD19 at the RP2D.

Condition or disease Intervention/treatment Phase
Lymphoma, B-Cell Biological: TAC01-CD19 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma
Estimated Study Start Date : May 2020
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2024

Arm Intervention/treatment
Experimental: TAC01-CD19
TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.
Biological: TAC01-CD19
Dose-escalating cohorts plus expansion groups

Primary Outcome Measures :
  1. Incidence of dose-limiting toxicities (DLTs) [ Time Frame: First 28 days after dosing ]
    Measurement of occurrence of study-defined DLTs

  2. Incidence of adverse events (AEs) [ Time Frame: Informed consent through 2 years after dosing ]
    Type, frequency, and severity of adverse events (AEs) and laboratory abnormalities

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed CD19+ Large B-Cell Lymphoma including Diffuse Large B-cell Lymphoma (DLBCL) not otherwise specified (including de novo and transformed lymphoma), Primary Mediastinal Large B-cell Lymphoma, High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangement per WHO 2016 classification.
  • Relapsed or refractory disease after greater than 2 lines of therapy including anthracycline and anti-CD20 therapy and either having failed autologous stem cell transplant (ASCT) or being ineligible for ASCT.
  • ECOG 0-1.
  • Adequate organ function.

Exclusion Criteria:

  • Prior treatment with any of the following: allogeneic bone marrow transplantation, gene therapy, adoptive cell transfer of any kind, including CAR T cells.
  • Active central nervous system (CNS) lymphoma involvement.
  • History or presence of clinically relevant CNS pathology.
  • Active inflammatory neurological disorders, autoimmune disease, or infections.
Layout table for additonal information
Responsible Party: Triumvira Immunologics, Inc. Identifier: NCT03880279    
Other Study ID Numbers: TAC01-CD19-01
First Posted: March 19, 2019    Key Record Dates
Last Update Posted: February 23, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin